The Canadian cannabis industry is just beginning to grow and develop. With marijuana legalization only a few days away, now is the time to invest in stocks that will play an important role in the new industry. One of the companies that should be a leader in Canada is Aphria Stock. Aphria Stock is a Canadian cannabis company that has been in the business for several years. It is a leader in its field and is worth investing in.

As one of Canada’s largest licensed medical marijuana producers, Aphria Inc. (TSX:APH)(OTCQB:APHQF) is one of the most intriguing marijuana stocks on the market today. The company’s stock trades at a very attractive valuation, but investors have questioned the ongoing viability of the business as governments crack down on the marijuana industry.

Last week, Aphria Inc.’s (TSX:APH) stock was on fire. During a single week, the stock went from $7.78 to $9.44 due to its latest quarterly results. This is a gain of 17.88% and shows investors that the company is actually doing something right. Although the company is doing well, it is still a risky stock to invest in, especially since it has lost about $430 million in market value.

word-image-8127 Prior to COVID-19 in the US and Canada, the cannabis industry did very well financially. The dynamics of the equity markets were focused on outperformance. Aphria is one of the largest cannabis companies with a high market capitalization. Last year, in August, APHA shares lost about 25% of their value.  Other big names have even halved their prices at this point. So, would it be a good idea to invest in Aphria shares now? Let’s take a look at ‘s recent performance and make a wise investment decision. What were the problems? In 2018, it was revealed that the internal management of benefited from the company’s acquisition of LATAM holding company , paying off millions in LATAM debt and issuing 15.6 million shares to .  However, the investigators argued that there was overpayment and that the executives of the company also did it to enrich their bank accounts. This decision was controversial, and even the Executive Director, Mr. Neufeld , developed the draft after this issue. The company even had to pay huge damages for the bad takeover. These events have led people to distrust the APHA. Latest statistics of Aphria Aphria announced on 29. July its results for the year 2020 (until the end of May 2020).  This report did not impress investors, as reported a loss of about C$98.8 million, just one-sixth of ‘s net income in the previous quarter. Investors were even quick to sell shares of APHA , but some analysts say that was a bad move. It is not good for a business to suffer unexpected losses. The company posted a net loss of 65% due to the impact of the global pandemic. The impairments of resulted in significant losses and even loss of earnings. The last earnings report of was not good, and so the share price of also fell. The year 2020 was where there was a lot of hope for the cannabis derivatives market. The coronavirus pandemic has disrupted the plans of many cannabis producers, and key players in the industry have reported multiple outages. Aphria has focused on vape products and has even delivered on its promise by becoming the leader in the vape industry in Ontario (a densely populated area). APRA is doing well in the adult recreational marijuana business and has a positive position in the company for gross sales in this segment in the fourth quarter. Another asset of APHA is its subsidiary CC Pharma. The company reported revenue of C$97.1 million for the most recent quarter ( ). Aphria ‘s position is still considered strong by some analysts. The shares may seem expensive , but they are affordable compared to competitors. Aphria could be a good buy and is among the best cannabis stocks to buy right now.Aphria (APHA) is a Canadian company that produces and sells medical marijuana. The company’s stock price has been rising lately. It is currently trading at $12 and as of this writing, has risen by more than 100% over the course of the last three months. (Cannabizarro is a market research company that provides the most accurate, unbiased and reliable data about the Cannabis Industry. You can learn more about us here .) There are many reasons why someone may be buying Aphria stock. Some may be in it for the long term. Others may have gotten sucked into the mania of the moment. Still others might be hoping to pump and dump the stock.. Read more about should i buy aphria or tilray and let us know what you think.

Frequently Asked Questions

Is Aphria a good buy right now?

Despite being one of the largest legal cannabis companies in the world, Aphria (NASDAQOTH: APHQF ) is flying under the radar. The market’s relative neglect of the stock is reflected in its price performance over the past year: Aphria stock is down about 20% since its peak in October, compared to a decline of just 2% for the broad Canadian market. Given the company’s strong prospects, it seems likely that this is an opportunity to buy low. Aphria Inc. (TSX:APH) is one of Canada’s largest licensed cannabis producers, specializing in the production, cultivation, and extraction of cannabis. The company is headquartered in Leamington, Ontario and has been in operation since 2014. Recently, the stock has been in the news for being involved in a conflict with short sellers. As a result, the stock price has been surging.  However, should investors buy the stock at these levels?

Is Aphria undervalued?

Aphria has been a pleasant surprise for investors who bought into the company early. The stock has increased by more than 400% since early 2018, when it was still trading for less than $2 per share. Now, some are wondering if it’s time to sell before it reaches a peak. While there are valid arguments for both sides of this debate, it is hard to deny that Aphria has a lot of positives going for it. Other Posts: 3 Aphria, Inc. (TSE:APHA) (OTCQB:APHQF) is a stock that has been on a bit of a roller coaster in recent months. The stock has a lot going for it, and many analysts believe the company is undervalued right now. (Aphria isn’t the only stock in the cannabis sector that warrants a second look. If you’re considering buying marijuana stocks, you may want to consider Canopy Growth Corporation (TSE:WEED) (NYSE:CGC) as well.)

Is APHA a buy or sell?

Aphria is a company that is still moving forward despite everything we are hearing about the marijuana market. It still has a lot of options and is a multibillion dollar business. It is still a good investment overall. However, that is a very important factor. This company is still in its early stages and is still growing. Aphria is one of Canada’s largest cannabis companies and this was in the news several times last week for different reasons. Firstly, it’s CEO Vic Neufeld was on CNBC and the company was the first Canadian licensed producer to make the list of the “Dirty Dozen” of most shorted stocks in Canada. Then, it announced a 50/50 joint venture with Liberty Health Sciences Inc (LHS.CN) (LHSIF). The stock has been doing great in the past week and the recent events have raised questions about its performance. Let’s take a look and see if Aphria is worth buying at current prices.

is aphria stock a good buy todayaphria stock forecast 2025is aphria a good stock to buy 2021should i buy aphria or tilrayaphria stock newsapha price target 2021,People also search for,Feedback,Privacy settings,How Search works,Tilray,Canopy Growth Corporation,Cronos Group,Village Farms Internation…,See more,is aphria stock a good buy today,aphria stock forecast 2025,is aphria a good stock to buy 2021,should i buy aphria or tilray,aphria stock news,apha price target 2021,tilray and aphria merger date,aphria stock price forum

You May Also Like

McGuire details $1.5M in funding to fight “worst” illegal cannabis grows in 3 counties

The California Cannabis Industry Association (CCIA) announced today that it has received…

The Last Mile to Federal Legalization

The cannabis industry in the United States is growing, yet it remains…

Researchers Weigh in on the Hype About MDMA Therapy

For a long time, MDMA, or ecstasy, was thought of as just…

High hopes for UNR cannabis education program

As more states legalize cannabis, the state of Nevada hopes to be…